# An Overview of Topical Treatment of Psoriasis, Variation and Adverse Effects

<sup>1</sup>Amani Ali Madkhali, <sup>2</sup>Nehad Khalaf Khawaji, <sup>3</sup>Amany Ibraheem Mashi, <sup>4</sup>Aisha Yahya Alkhaldy, <sup>5</sup>Tahani Ahmed Moafa, <sup>6</sup>Abdulrhman Jaber Hakami, <sup>7</sup>Zainab Ahmad Jafari, <sup>8</sup>Mohannad Faisal Tobaigy, <sup>9</sup>Amwaj Jabir Mohanna, <sup>10</sup>Ebtesam Eissa Madkhali, <sup>11</sup>Abdu Mohammed Hamdi, <sup>12</sup>Hatim Saeed Alessa

Abstract: This review was aimed to Overview the topical treatments for psoriasis, as well as the evidence and rationale for combining therapies of these topical treatments. Also intended to discuss the efficiency and adverse effect of various mentioned topical therapies. We conducted a comprehensive literature searches via PubMed and Embase databases, searching relevant studies concerning with topical therapies for psoriasis published in English up to December 2016. Our search was performed using the search term "psoriasis" combined with "topical treatment." Furthermore, we searched references lists of those chosen articles for more relevant studies to be included in present review. Only studies with human subjects were included in this review

Topical When utilized properly as well as has the benefit of limited systemic effects, therapy is effective and also secure. When suggesting a topical therapy one has to consider a number of factors, including patient inspiration as well as understanding, lorry of medicament, quantity of treatment called for and require for dressings. Topical treatment could be greasy, bothersome, difficult as well as time-consuming for patient. When topical therapies fall short, improving adherence to topical treatments is vital to promote better clinical result; clinicians should constantly take into consideration non-adherence. Topical therapy of psoriasis has actually evolved from the ageold applications of tar and also dithranol to the extra efficacious and also appropriate choices of topical corticosteroids, and also vitamin D analogues.

Keywords: Topical Treatments for Psoriasis, Greasy, Bothersome.

#### 1. INTRODUCTION

Psoriasis is a chronic inflammatory disease influencing 1 - 2% of the population worldwide <sup>(1)</sup>. Clinically, psoriasis offers as well-demarcated, elevated, erythematous, flaky plaques mostly influencing the scalp, trunk as well as extensor surface areas; nevertheless, any type of body site can likewise be entailed. Psoriasis is an emotionally incapacitating disease as well as could have profound impact on patients' lifestyle no matter the degree of body area (BSA) involvement. Mild-to-moderate psoriasis influences ~ 80% of the complete psoriasis population globally <sup>(2)</sup>. Topical medicine is generally utilized as initial line of therapy in light psoriasis yet could additionally be made use of concomitantly with phototherapy, organic or systemic therapies for moderate-to-severe psoriasis. Treatment of psoriasis ought to constantly be appropriate to its severity as well as importance to that person: It must never be much more unpleasant, intolerable, or dangerous than the disease itself <sup>(3)</sup>. Topical therapies include vitamin D analogues, topical corticosteroids, tar-based prep works, dithranol, salicylic acid, as well as topical retinoids <sup>(4,5,6)</sup>. Treatment adherence has actually been acknowledged as an important problem in the management of chronic inflammatory skin diseases such as psoriasis. A majority of therapy failures might be attributed to poor adherence to drugs (7,8). The principle of adherence is different from the idea of conformity; adherence is the degree to which patients utilize drug as recommended by their health care provider,

Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 - March 2017, Available at: www.researchpublish.com

conformity is a slightly different concept implying that the passive patient follows orders from the company <sup>(9)</sup>. Therapeutic alternatives are plentiful; frequent advances have actually been made in topical therapies, systemic therapies, as well as photo-therapies. Since an approximated 75% of psoriatic patients have mild-to-moderate disease,1 topical treatments continue to be one of the most extensively made use of. These drugs are efficacious in mild-to-moderate disease as well as prompt less issue about systemic adverse effects <sup>(8,9)</sup>.

This review was aimed to Overview the topical treatments for psoriasis, as well as the evidence and rationale for combining therapies of these topical treatments. Also intended to discuss the efficiency and adverse effect of various mentioned topical therapies.

#### 2. METHODOLOGY

We conducted a comprehensive literature searches via PubMed and Embase databases, searching relevant studies concerning with topical therapies for psoriasis published in English up to December 2016. Our search was performed using the search term "psoriasis" combined with "topical treatment." Furthermore, we searched references lists of those chosen articles for more relevant studies to be included in present review. Only studies with human subjects were included in this review

#### 3. RESULTS

### > Overview of Topical therapies for psoriasis:

Topically application or dressings are often used to enhance drug distribution. This is particularly real of corticosteroids (10). The option of specific dressings will be determined by regional accessibility and also patient choice. Moisturizers provide a helpful and also secure adjunct in the treatment of psoriasis. Enhancing skin hydration is generally identified to boost symptoms and signs of psoriasis (11). Medical trials involving topical corticosteroids showed a sugar pill response of 15 - 47%, indicating that the emollient impact of the lorry supplies a significant restorative benefit (12). The choice of emollient will certainly be led by the seriousness of xerosis and also the choices of both the medical professional and patient. The emollient is usually used 1 - 3 times a day. There are no well-known contraindications to emollient therapy, and also emollients are considered risk-free in children, pregnancy as well as breast-feeding.

#### **Severity Assessment:**

The administration of psoriasis needs the medical professional to carry out a trustworthy and accurate evaluation of disease severity. Extent of psoriasis has generally been figured out by the physical extent of the disease, psychosocial impairment in lifestyle, and also previous feedback to treatment. A globally accepted uniform racking up system is of utmost importance in the contrast of treatment results obtained in professional tests to ensure that the understanding can be applied in medical practice, as presently the majority of clinicians do not make use of the scientific trials' criteria in daily technique. In simple terms, moderate psoriasis has actually been specified as affecting less than 5% of the body area (BSA), with moderate disease impacting 5 - 10%, and also extreme disease above 10% (13). While percent BSA involvement, where the location of the patient's palm (outstretched hand consisting of all 5 digits) stands for regarding 1% of overall BSA, is a convenient and also fast tool to analyze extent of involvement, it does not think about private attributes of induration, scaling and also erythema, or impact on the quality of life; every one of these are considerable indications of disease morbidity. The Psoriasis Assessment and Severity Index (PASI) was established for usage in assessing the feedback to a retinoid in a medical trial (14). The various presentations of psoriasis require a variable strategy to treatment and the existing therapy idea advocates that the sort of treatment suggested need to be appropriated to disease intensity. There is a broad range of treatments available for the treatment of psoriasis, either topical or systemic representatives, the usage of topical therapy (Figure 1) (15) continues to be an essential element of the management of practically all psoriasis patients. While light disease is commonly treated only with topical representatives, using topical treatment as adjuvant therapy in moderate-to-severe disease might also be useful and could possibly reduce the amount of phototherapy or systemic agent required to accomplish satisfying disease control (15).

Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 - March 2017, Available at: www.researchpublish.com




Figure 1: Topical therapy for management of psoriasis. (15)

Topical therapies for severity levels of psoriasis (f mild-to-moderate) involve a great number of different topical agents, including summarized in (**Table 1**) <sup>(16,17,18)</sup>:

Table 1: Topical therapies for severity levels of psoriasis.

1)	Emollients;
2)	Tars;
3)	Dithranol;
4)	Topical retinoids (Tazarotene);
5)	Calcineurin inhibitors (pimecrolimus and tacrolimus);
6)	Keratolytics (salicylic acid, urea);
7)	Topical vitamin D analogues (calcitriol, tacalcitol, and calcipotriol);
8)	Topical corticosteroids.

# > Corticosteroids Topical for psoriasis & Mechanism of Action:

Given that their introduction to dermatology, greater than 50 years earlier, topical corticosteroids have actually come to be the mainstay of therapy of various dermatoses consisting of psoriasis, generally due to their immunosuppressive, anti-inflammatory as well as antiproliferative residential or commercial properties, that makes this course of medications an useful therapy for this immune-mediated disease (19,20). Although topical corticosteroids are an essential part of the

Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 - March 2017, Available at: www.researchpublish.com

psoriasis therapeutic armamentarium, limitations as a result of the occurrence of popular cutaneous damaging impacts such as degeneration, striae and/or telangiectases, and prospective systemic adverse occasions avoid their optimum long-term and also comprehensive usage. Approaches such as the weekend-only/pulse therapy regimen or combining topical corticosteroids with other topical agents could enhance their effectiveness as well as safety account over longer periods (21,22). The objective of the therapy is to reduce the degree and intensity of psoriasis to the point at which it is no longer destructive to a patient's lifestyle. Therapy option must constantly be tailored to match the private patient's demands and his expectations. When used under these situations, a topical treatment routine is most likely to produce an acceptable clinical result (16,18). Corticosteroids stay first-line therapy in the management of all grades of psoriasis, both as monotherapy or as an enhance to systemic therapy. They are available in a wide variety of preparations consisting of gel, cream, ointment, foam, spray lotion and oil, and also a new and also innovative car (**Table 2**) (16,22).

**Table 2: Corticosteroid classification system** (16,22)

Class	Name
Superpotent	Betamethasone dipropionate glycol 0.05%
Class I USA; class I UK;	Clobetasol 17-propionate 0.05%
class IV Germany	Halobetasol propionate 0.05%
Class IV Germany	Transpectasor propromate 0.05 /0
High potency	Amcinonide 0.1%
Class II/III USA; class II UK;	Betamethasone dipropionate 0.05%
class III Germany	Desoximetasone 0.25%
Class III Germany	Diflucortolone valerate 0.1%
	Fluocinonide 0.05%
	Halcinonide 0.1%
	Mometasone furoate 0.1%
	Triamcinolone acetonide 0.5%
	Thankinolone acetonide 0.5%
Moderate potency	Betamethasone dipropionate 0.05%
Class IV/V USA; class III	Betamethasone valerate 0.1%
UK; class II Germany	Clobetasone 17-butyrate 0.05%
Cit, class if Germany	Desonide 0.05%
	Desoximetasone 0.05%
	Fluocinonide 0.025%
	Hydrocortisone 17-valerate 0.2%
	Prednicarbate 0.1%
	Triamcinolone acetonide 0.1%
	Transmitted deciding 0.170
Low potency	Betamethasone valerate 0.05%
Class VI/VII USA; class IV	Desonide 0.05%
UK; class I Germany	Fluocinonide 0.01%
,	Hydrocortisone 1.0%, 2.5%
	Hydrocortisone acetate 0.5%, 1.0%
	Prednicarbate 0.05%
	Triamcinolone acetonide 0.025%
	Transferred dectoring 0.025 /0

**Mechanism of action,** Corticosteroids bind to certain receptor proteins as well as this complicated engages with certain DNA series, glucocorticoid reaction elements, to regulate the expression of corticosteroid-responsive genetics. This causes a myriad of impacts, including transformed cytokine expression and also T cell inhibition. Topical corticosteroids are offered in a wide variety of vehicles, consisting of lotions, lotions, gels, creams, powders, hair shampoos, impregnated tapes (including a recent betamethasone valerate 0.1% occlusive preparation), and extra just recently sprays as well as foams. The choice of the car depends upon the anatomical sites of the location to be treated. As a whole, ointments have actually commonly been considered to be extra efficient due to their occlusive nature which results in improved

penetration. The addition of propylene glycol enhances the solubility of steroids in the automobile; thus, boosting the medicine penetration. Nevertheless, they are greasy in nature as well as absence aesthetic allure. Lotions are much less greasy and much less occlusive compared to lotions, and cosmetically extra acceptable to the patients. Therefore, lotions might be recommended for daytime application, while lotions could be applied in the evening. Lotions, foams and gels are useful for dealing with hair-bearing locations, such as the scalp. Foams have been shown to have equivalent clinical effectiveness to standard vehicles such as lotions (23). When applied to the skin, the body heat breaks down the thermolabile foam, transferring the energetic ingredient straight on the skin. This causes a greater efficacy as well as reduced systemic poisoning compared to standard lorries. Randomized multicentric double-blinded placebo-controlled trials have actually also shown efficiency of betamethasone valerate 0.12% foam in scalp psoriasis (10). One study showed comparable outcomes when utilized for the therapy of non-scalp psoriasis, removing the need for separate scalp and also body solutions (11). Clobetasol propionate, when utilized as a 0.05% measured dosage spray, has actually been shown to be a practical choice to typical prep works. In a recent large community-based 4-week empirical research (COBRA test) of 1,254 patients, clobetasol propionate spray demonstrated excellent effectiveness with roughly 90% of patients being pleased with the treatment (24). The strength of topical corticosteroids is boosted by chemical modification of the steroid, e.g. acetylation, methylation and halogenation. Occlusion by applying a hydrocolloid dressing also raises penetration as well as effectiveness (25) In general, the high-potency corticosteroids are scheduled for the treatment of inflammatory as well as recalcitrant lesions on areas such as elbows, knees, lumbosacral area, soles and hands, with or without occlusion. The lower potency steroids are chosen in thinner skinned locations, such as the face as well as flexures. To prevent the risk of unfavorable results, the weakest corticosteroid that is possibly effective must be used, particularly as upkeep therapy. In scientific practice, particularly in the USA, the huge bulk of patients are treated at first with high-potency topical corticosteroids. In a research on using high-potency corticosteroids in a scholastic method (26), it was observed that 79% of patients with psoriasis were recommended topical corticosteroids, more than half of which got a high-potency steroid; 11% additionally obtained systemic treatment. Prolonged use topical corticosteroids is limited by assumed tachyphylaxis, a sensation where medicines revealing a positive scientific action lose their performance after prolonged use.

If topical corticosteroids are utilized inappropriately or for prolonged periods, side impacts are of problem. Atrophic changes prevail and include thinning of the skin, telengiectasias, striae (Figure 2), purpura and very easy bruising. Various other changes consist of acneiform changes, perioral dermatitis, rosacea, call dermatitis, hypertrichosis, pigmentary modifications as well as postponed wound-healing. Fungal infections could be masked, leading to tinea incognito (26).



Figure 2: Striae secondary to topical corticosteroid usage.

#### > Vitamin D Analogues & mechanism of action and adverse effects:

When a patient's psoriasis boosted complying with administration of 1-α hydroxyl vitamin D3 for therapy of weakening of bones (27), vitamin D3 was first observed to be valuable in psoriasis. Calcipotriol (additionally known as calcipotriene) was the first vitamin D analogue to be used in psoriasis. Subsequently, calcitriol (1,25 dihyroxy vitamin D3) and tacalcitol were created, with maxacalcitol as well as tisocalcitate most recently included in the armamentarium. Vitamin D

Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 - March 2017, Available at: www.researchpublish.com

analogues have now end up being a first-line treatment for plaque psoriasis, being even more efficacious and also cosmetically appropriate compared to older therapies like tar and also dithranol, and of equivalent strength to the midhigh range of potency of topical corticosteroids. Vitamin D analogues bind to the vitamin D receptor, which consequently binds to vitamin D response elements. This interaction results in modification in transcription of vitamin-Dresponsive genetics, leading to inhibition of keratinocyte proliferation as well as excitement of keratinocyte differentiation. Topical calcitriol also decreases intercellular attachment particle ICAM-1 expression on keratinocytes and T cell infiltration (28). While the preliminary clinical feedback is slower than with the more powerful corticosteroids, it may be observed within 2 weeks, with optimum benefit usually seen at 6-- 8 weeks.

Calcipotriol is offered in a lotion base, which is one of the most efficient kind. It is likewise readily available in a less oily cream base as well as in a remedy kind for hair-bearing areas, such as the scalp. Calcipotriol ointment made use of as 50  $\mu$ g/g applied twice daily has been revealed to be scientifically effective (299). Temporary therapy with calcitriol might be as reliable as a mid- to high-potency corticosteroid, yet as compared to super-potent corticosteroids, calcipotriol is less efficient. Calcitriol is the active type of vitamin D. Calcitriol ointment, applied twice daily as a 3  $\mu$ g/g ointment, has actually been shown to be clinically risk-free as well as well endured in long-lasting research studies (30). Tacalcitol is an artificial vitamin D analogue, readily available as a 4  $\mu$ g/g ointment. Applied once daily, it transcends to sugar pill (31), however when compared with calcipotriol, it was located to be less reliable. Nevertheless, its side effects are marginal, being well tolerated in sensitive skin areas (32). A multicentric randomized controlled trial disclosed that although 0.05% betamethasone dipropionate was a little a lot more efficacious than calcitriol, those receiving calcitriol remained in remission longer and fewer patients called for reinstitution of treatment (33).

Adverse Effects, Vitamin D analogues are typically well tolerated, with the most common adverse effects being irritant get in touch with dermatitis, specifically in locations such as the face. This is seen in concerning one third of patients, and shows up to minimize with continuous therapy. Tacalcitol is the least annoying derivative. Dilution of calcipotriol with petrolatum or concomitant therapy with a topical corticosteroid works in protecting against irritability in sensitive areas. Vitamin D analogues also appear to have an impact on calcium and bone metabolic rate and also may bring about hypercalcemia and also hypercalciuria. Tracking of product or urinary calcium degrees is therefore advised if calcipotriol is provided to patients for extended periods at the optimum dosage and also in patients with abnormal calcium metabolic process.

# 4. CONCLUSION

Topical When utilized properly as well as has the benefit of limited systemic effects, therapy is effective and also secure. When suggesting a topical therapy one has to consider a number of factors, including patient inspiration as well as understanding, lorry of medicament, quantity of treatment called for and require for dressings. Topical treatment could be greasy, bothersome, difficult as well as time-consuming for patient. When topical therapies fall short, improving adherence to topical treatments is vital to promote better clinical result; clinicians should constantly take into consideration non-adherence, topical therapy of psoriasis has actually evolved from the age-old applications of tar and also dithranol to the extra efficacious and also appropriate choices of topical corticosteroids, and also vitamin D analogues.

#### **REFERENCES**

- [1] Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509
- [2] Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
- [3] Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. Journal of Dermatological Treatment 2003;14(1):8–13.
- [4] Kinney MA, Feldman SR. What's new in the management of psoriasis? G Ital Dermatol Venereol 2009; 144: 103–117
- [5] Devaux S, Castela A, Archier E, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 3): 52–60.

- Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 March 2017, Available at: www.researchpublish.com
- [6] Serup J, Lindblad AK, Maroti M et al. To follow or not to follow dermatological treatment a review of the literature. Acta Derm Venereol 2006; 86: 193–197.
- [7] Serup J, Lindblad AK, Maroti M et al. To follow or not to follow dermatological treatment a review of the literature. Acta Derm Venereol 2006; 86: 193–197.
- [8] Carroll CL, Feldman SR, Camacho FT, Balkrishnan R. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895–897.
- [9] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 4: 353.
- [10] Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS: Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628–632.
- [11] Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR: A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002;41:269–274.
- [12] Langley RG, Ellis CN: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563–569.
- [13] Menter A, Griffiths CEM: Current and future management of psoriasis. Lancet 2007;370:272-284.
- [14] Fredrickson T, Petterson U: Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157:238-244.
- [15] Uva L, Miguel D, Pinheiro C, et al. Mechanisms of Action of Topical Corticosteroids in Psoriasis. *International Journal of Endocrinology*. 2012;2012:561018. doi:10.1155/2012/561018.
- [16] Laws PM, Young HS. Topical treatment of psoriasis. *Expert Opinion on Pharmacotherapy*. 2010;11(12):1999–2009.
- [17] Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. *Journal of the European Academy of Dermatology and Venereology*. 2011;25(Supplement 4):3–8.
- [18] Reich K, Bewley A. What is new in topical therapy for psoriasis? Journal of the European Academy of Dermatology and Venereology. 2011;25(Supplement 4):15–20.
- [19] Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. *Journal of the European Academy of Dermatology and Venereology*. 2012;26(Supplement 3):36–46.
- [20] Van De Kerkhof P, Kragballe K, Segaert S, Lebwohl M. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council. *Journal of the European Academy of Dermatology and Venereology*. 2011;25(10):1130–1139.
- [21] Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K. Topical corticosteroids in psoriasis: strategies for improving safety. *Journal of the European Academy of Dermatology and Venereology*. 2010;24(2):119–124.
- [22] Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. *Experimental Dermatology*. 2006;15(6):406–420.
- [23] Feldman SR, Sangha N, Setaluri V: Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol 2000;42:1017–1020.
- [24] Menter A: Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 2007;80:12–19.
- [25] Volden G, Kragbelle K, van de Kerkhof PC, Aberg K, White RJ: Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatol Treat 2001;12:141–144.
- [26] Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleisher AB Jr, Feldman SR: Class I topical corticosteroid use by psoriasis patients in an academic practice. J Dermatolog Treat 2004;15:235–238.

- Vol. 4, Issue 2, pp: (1802-1809), Month: October 2016 March 2017, Available at: www.researchpublish.com
- [27] Morimoto S, Kumahara Y: A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 1985;35:51–54.
- [28] Lu I, Gilleadeau P, McLane JA, Heftler N, Kamber M, Gottlieb S, Krueger JG, Gottlieb AB: Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. J Cutan Pathol 1996;23:419–430.
- [29] Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ: Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27:983–988.
- [30] Gerritsen MJ, van de Kerkhof PCM, Langner A: Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol 2001;144(suppl 58): 17–19.
- [31] Van de Kerkhof PC, Werfel T, Haustein UF, et al: Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, doubleblind study on efficacy and safety. Br J Dermatol 2002;135:758–765.
- [32] Scarpa C: Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996;6:142–146.
- [33] Camarasa JM, Ortonne JP, Dubertret L: Calcitriol shows greater persistence of treatment effect than betamethasone diproprionate in topical psoriasis therapy. J Dermatol Treat 2003;14:8–13.